BTIG Research Boosts Apogee Therapeutics (NASDAQ:APGE) Price Target to $128.00

Apogee Therapeutics (NASDAQ:APGE) had its target price hoisted by equities research analysts at BTIG Research from $115.00 to $128.00 in a research note issued to investors on Monday, Marketbeat.com reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 63.58% from the stock’s current price.

A number of other research analysts also recently commented on the company. Mizuho started coverage on Apogee Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $105.00 target price for the company. Stephens started coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 16th. They set an “overweight” rating and a $95.00 price objective for the company. Wall Street Zen downgraded shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Apogee Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $103.64.

Apogee Therapeutics Stock Up 1.0%

APGE opened at $78.25 on Monday. The company has a market capitalization of $5.35 billion, a PE ratio of -17.87 and a beta of 1.41. The firm has a 50-day simple moving average of $69.57 and a two-hundred day simple moving average of $51.22. Apogee Therapeutics has a 52 week low of $26.20 and a 52 week high of $80.99.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, November 10th. The company reported ($1.11) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.03. As a group, sell-side analysts expect that Apogee Therapeutics will post -3.09 earnings per share for the current year.

Insider Buying and Selling

In other Apogee Therapeutics news, insider Carl Dambkowski sold 10,900 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $75.00, for a total value of $817,500.00. Following the transaction, the insider owned 271,108 shares of the company’s stock, valued at $20,333,100. This represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $75.01, for a total value of $3,000,400.00. Following the sale, the chief executive officer owned 1,232,987 shares of the company’s stock, valued at approximately $92,486,354.87. This trade represents a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 101,685 shares of company stock worth $7,179,630. Insiders own 42.77% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in APGE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Apogee Therapeutics by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after buying an additional 694 shares in the last quarter. Millennium Management LLC increased its position in shares of Apogee Therapeutics by 100.0% during the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after acquiring an additional 130,164 shares during the period. Octagon Capital Advisors LP bought a new stake in shares of Apogee Therapeutics during the first quarter valued at approximately $399,752,000. Woodline Partners LP boosted its holdings in shares of Apogee Therapeutics by 4.5% in the first quarter. Woodline Partners LP now owns 1,061,053 shares of the company’s stock valued at $39,641,000 after purchasing an additional 45,445 shares during the period. Finally, Rhumbline Advisers grew its stake in Apogee Therapeutics by 3.2% in the first quarter. Rhumbline Advisers now owns 54,385 shares of the company’s stock worth $2,032,000 after purchasing an additional 1,665 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors.

Key Stories Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Interim Phase 1b results show rapid, durable suppression of FeNO through 16 weeks (and through 32 weeks for patients with follow-up), supporting potential 3- or 6-month dosing and reinforcing zumilokibart as a potential best‑in‑class anti‑IL‑13 candidate — a clear clinical-catalyst for valuation upside. Apogee Therapeutics Announces Positive Interim Results (GlobeNewswire)
• Positive Sentiment: Analyst upgrade: BTIG raised its price target on APGE to $128 with a Buy rating, giving a sizable upside scenario that can support further investor interest and higher valuations if follow-on data remains strong. APGE price target raised by BTIG (The Fly)
• Neutral Sentiment: Company hosted a conference call and management discussion / transcript is available — useful for detail on patient numbers, safety, durability, and planned next steps; investors should parse the transcript for sample size and endpoints before extrapolating commercial potential. Apogee Therapeutics Phase 1b results transcript (Seeking Alpha)
• Negative Sentiment: Mixed market reaction: some outlets reported that APGE stock fell after the asthma data was released — likely reflecting short‑term profit‑taking, investor caution about early‑stage biomarker data (sample size, clinical endpoints, safety, or commercial pathway), or expectations already priced in. Monitor follow-up detailed data and Q&A that address size and clinical relevance. Apogee Therapeutics stock falls after asthma trial data (Investing.com)

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.